In The News
Dealing with Food Allergies?
What Happened in My Study?
FDA Approves First Generic of Symbicort to Treat Asthma and COPD
Today, the U.S. Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions: asthma in patients six years of age and older; and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. This complex generic drug-device combination product, which is a metered-dose inhaler, should not be used to treat acute asthma attacks.
The most common side effects associated with budesonide and formoterol fumarate dihydrate oral inhalation aerosol for those with asthma are nasopharyngitis (swelling of nasal passages and back of throat), headache, upper respiratory tract infection, pharyngolaryngeal (nose and mouth) pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis (thrush). For those with COPD, the most common side effects are nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection.
We at Allergy & Asthma Medical Group and Research Center understand the concerns regarding patient and staff safety surrounding the COVID-19 pandemic. For your safety, we are following our local health department and the CDC guidelines.
Here are a few of the things we have put in place at our research study site:
- Facial coverings are required for all patients and staff
- Limited number of individuals are at the research site at one time
- Any patients or guests with COVID-19 symptoms will have their appointments rescheduled
Contact us if you would like more information on our safety measures, we are following our local health department and the CDC guidelines.